Cargando…

Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers

Clinical trials and real-world evidence on COVID-19 vaccines have shown their effectiveness against severe disease and death but the durability of protection remains unknown. We analysed the humoral and T-cell immune responses in 110 healthcare workers (HCWs) vaccinated according to the manufacturer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonnet, Benjamin, Chabrolles, Hélène, Archimbaud, Christine, Brebion, Amélie, Cosme, Justine, Dutheil, Frédéric, Lambert, Céline, Junda, Maud, Mirand, Audrey, Ollier, Amandine, Pereira, Bruno, Regagnon, Christel, Vidal, Magali, Evrard, Bertrand, Henquell, Cécile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926062/ https://www.ncbi.nlm.nih.gov/pubmed/35309363 http://dx.doi.org/10.3389/fimmu.2022.842912

Ejemplares similares

Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection
por: Bingula, Rea, et al.
Publicado: (2023)

Comparative T and B immune responses of four different anti-COVID-19 vaccine strategies 6 months after vaccination
por: Bonnet, Benjamin, et al.
Publicado: (2022)

Evidence of co-infections during Delta and Omicron SARS-CoV-2 variants co-circulation through prospective screening and sequencing
por: Combes, Patricia, et al.
Publicado: (2022)

Severe Pneumonia Associated with Adenovirus Type 55 Infection, France, 2014
por: Lafolie, Jérémy, et al.
Publicado: (2016)

A large-scale outbreak of hand, foot and mouth disease, France, as at 28 September 2021
por: Mirand, Audrey, et al.
Publicado: (2021)

Utility of the Basophil Activation Test Using Gly m 4, Gly m 5 and Gly m 6 Molecular Allergens for Characterizing Anaphylactic Reactions to Soy
por: Evrard, Bertrand, et al.
Publicado: (2022)

Validation of a SARS-CoV-2 RT-PCR assay: a requirement to evaluate viral contamination in human semen
por: Chabrolles, Hélène, et al.
Publicado: (2022)

Improvement of the Management of Infants, Children and Adults with a Molecular Diagnosis of Enterovirus Meningitis during Two Observational Study Periods
por: Archimbaud, Christine, et al.
Publicado: (2013)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
por: Miyazaki, Ryoichi, et al.
Publicado: (2023)

Coxsackievirus A6 Recombinant Subclades D3/A and D3/H Were Predominant in Hand-Foot-And-Mouth Disease Outbreaks in the Paediatric Population, France, 2010–2018
por: Tomba Ngangas, Stéphanie, et al.
Publicado: (2022)

Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2021)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

Aspects of Humoral Immunity after Vaccination with Bnt162b2: A Small Study
por: GIUBELAN, LUCIAN-ION, et al.
Publicado: (2022)

Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases
por: Leung, Daniel, et al.
Publicado: (2023)

Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2022)

Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis
por: Dekervel, Marine, et al.
Publicado: (2021)

Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients
por: Agur, Timna, et al.
Publicado: (2022)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer
por: Di Noia, V., et al.
Publicado: (2022)

Serum C reactive protein predicts humoral response after BNT162b2 booster administration
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
por: Costard-Jäckle, Angelika, et al.
Publicado: (2022)

Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2
por: Rammauro, Florencia, et al.
Publicado: (2022)

Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
por: Dalla Gasperina, Daniela, et al.
Publicado: (2023)

Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, following Vaccination with BNT162b2
por: Fylaktou, Asimina, et al.
Publicado: (2023)

Ambulatory Pediatric Surveillance of Hand, Foot and Mouth Disease as Signal of an Outbreak of Coxsackievirus A6 Infections, France, 2014–2015
por: Mirand, Audrey, et al.
Publicado: (2016)

A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response
por: Masset, Christophe, et al.
Publicado: (2021)

Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
por: Lukaszuk, Krzysztof, et al.
Publicado: (2021)

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2
por: Dann, Eldad J, et al.
Publicado: (2021)

Humoral Response of Patients With Autoimmune Rheumatic Disease to BNT162b2 Vaccine: A Retrospective Comparative Study
por: Alsaed, Omar, et al.
Publicado: (2022)

Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail populations
por: Campagna, Roberta, et al.
Publicado: (2022)

Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines
por: Mavrovouniotis, Ilias, et al.
Publicado: (2023)

Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients
por: De Cagna, Maria Rosaria, et al.
Publicado: (2023)

The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
por: Cohen, Idan, et al.
Publicado: (2023)

Humoral and Cellular Response and Associated Variables Nine Months following BNT162b2 Vaccination in Healthcare Workers
por: Syrimi, Natalia, et al.
Publicado: (2023)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5df8t3dn5iufu8f1mhjl4vln47